Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) General Information

Description

Exclusive rights to a gene therapy targeting GUCY2D-associated Leber congenital amaurosis, a genetic eye disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 280 South Magnum Street
  • Suite 350
  • Durham, NC 27701
  • United States
Primary Industry
Buildings and Property
Acquirer
Atsena Therapeutics
Corporate Office
  • 280 South Magnum Street
  • Suite 350
  • Durham, NC 27701
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights)‘s full profile, request access.

Request a free trial

Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) FAQs

  • Where is Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) headquartered?

    Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) is headquartered in Durham, NC.

  • What industry is Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) in?

    Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights)’s primary industry is Buildings and Property.

  • Is Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) a private or public company?

    Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) is a Private company.

  • What is Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights)’s current revenue?

    The current revenue for Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) is .

  • When was Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) acquired?

    Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) was acquired on 29-Jul-2020.

  • Who acquired Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights)?

    Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) was acquired by Atsena Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process